 A patient with MCL1 amplified endometrial cancer achieved partial response PR with 92 target tumor shrinkage on singe agent fadraciclib A patient with MCL1 amplified endometrial cancer achieved partial response PR with 92 target tumor shrinkage on singe agent fadraciclib 